



Short version of press release from Emotra AB
Gothenburg May 28, 2013

Emotra's share issue completed

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

During the Extra Shareholders Meeting, January 11 2013, the Board of Emotra was authorized to decide on issues of new shares, to be carried out not later than at the date of the next Annual General Meeting. Based on this authorization the Board decided to issue 1 382 690 new shares at 7,20 SEK per shares and at the same time apply to AktieTorget for listing of the share.

The issue of new shares has now been finalized and strengthened the liquidity of the company. In total 499 145 new shares were issued for a total sum of 3,6 MSEK, before cost.

“The strengthening of our cash situation will be enough for the company to carry out our plans for clinical evaluations, in cooperation with 15 European top teams for the purpose of preparing the coming market introduction, says Claes Holmberg, President of Emotra.”

When the support for EDOR from these clinical teams, is strong enough, the method will be launched in Europe. This can certainly happen before all clinics have completed their studies. CE-marking of the product will be finalized during the next six months. All work in Emotra will be performed in a small organization and at a low cost level.

The psychiatric care has relevant preventive actions and resources to use when risk for suicide has been identified. Unfortunately there are today no accurate methods for the identification of risk patients, with the use of EDOR this difficult diagnostic problem can be solved. The test does not take more than 15 minutes. With necessary preparations, the total time is 30 minutes. The introduction of EDOR as a clinical routine procedure has the potential to substantially reduce the number of suicides and suicide attempts in the world.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se or

Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, lars@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se